… who developed brain metastases between January 1, 2008, … TKI-naïve patients with newly
diagnosed brain metastases, … radiotherapy (RT) after intracranial progression on EGFR-TKI, or …

… barrier (BBB) and inherent chemotherapy resistance of brain metastases (2). The efficacy of
chemotherapy is more evident in treatment-naïve patients. Single-agent chemotherapy drugs…

… Seventy-seven EGFR-TKI-naive patients were started on either gefitinib (n = 55) or
erlotinib (n = 22) in our hospital from April 2010 to April 2016. Among the patients with …

… This study evaluated the efficacy of three epidermal growth factor receptor–tyrosine
kinase inhibitors (EGFR-TKIs) in preventing and treating BM in patients with EGFR mutation-positive …

… , while incidence of disease recurrence in the brain after response to gefitinib has been also
… TKI treatment for asymptomatic synchronous brain metastases in chemotherapy-naïve never…

… brain metastases (BM), compared to 38% in EGFR wild-type patients. First-generation
tyrosine kinase inhibitors … II trial of 109 treatment-naïve, advanced or metastatic, EGFR-mutant, …

… It may be that the concentration of TKI in the CSF is sufficient to inhibit treatment-naive,
non–… high potency of kinase inhibition against EGFR, HER2, and ErbB4 kinases with 50% …

… in treatment‐naïve patients are common following treatment … : Management of brain
metastases in epidermal growth factor … with an EGFR inhibitor or radiotherapy (either whole‐brain …

… The efficacy of tyrosine kinase inhibitors (TKIs) with and without radiotherapy (RT) has not …
in patients with brain metastases from epidermal growth factor receptor-mutant TKI naïve non-…

… treatments for such metastases may be intolerable to some. Epidermal growth factor
receptor (EGFR) tyrosine kinase … who receive an EGFR tyrosine kinase inhibitor (TKI) have a …